BioMarck Pharmaceuticals
Durham
About BioMarck Pharmaceuticals
BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and a Phase 2 study of the efficacy of BIO-11006 in COPD patients. Data from the Phase 2 study demonstrated proof-of-concept of BIO-11006. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology, and his co-workers.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.5M
- Last round: Series Unknown (Feb 2017)
- Website: biomarck.com
- Phone: (919) 768-1335
Industries & Categories
Biopharma, Biotechnology, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/biomarck-pharmaceuticals-43693 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.